Icon

TREANDA (nda022249)- (25MG/VIAL,100MG/VIAL)

BENDAMUSTINE HYDROCHLORIDE CEPHALON
25MG/VIAL,100MG/VIAL
Yes Yes
2031-Apr-26 2013-Mar-20
2015-Mar-20 None
None No
TREANDA is an alkylating drug indicated for treatment of patients with:  Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.  Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
9 6 5
Total Other Developers 1
Drugs with Suitability No
25MG/VIAL ** ** - - -
100MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***
****** ****** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.